Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.

abstract：:We studied serum lipid and lipoprotein changes occurring during chemotherapy in 57 patients with chemosensitive cancers, including 18 malignant lymphomas, 18 breast carcinomas, 14 small-cell lung carcinomas, and 7 urothelial-cell carcinomas. Patients who responded favorably to chemotherapy demonstrated a significant i...

journal_title：Cancer chemotherapy and pharmacology

authors： Alexopoulos CG,Pournaras S,Vaslamatzis M,Avgerinos A,Raptis S

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:To investigate the effect of the antihistamine ketotifen on multidrug resistance in human breast cancer cells and doxorubicin toxicity in mice. METHODS:Clonogenicity assays were used to test the effect of ketotifen on human multidrug resistant breast cancer cell lines exposed to chemotherapeutic agents. Flow c...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Berger SA

更新日期：2003-05-01 00:00:00

abstract：PURPOSE:To assess the translational value of anticancer preclinical models, we retrospectively investigated the relationships between preclinical data and clinical response rate for 42 small-molecule targeted anticancer drugs approved by the US FDA from 2001 to 2018. METHODS:For 42 FDA-approved drugs, relevant pre-cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu WA,Yu L,Morcos PN,Mercier F,Brennan BJ

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS:Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methot...

journal_title：Cancer chemotherapy and pharmacology

authors： Izbicka E,Diaz A,Streeper R,Wick M,Campos D,Steffen R,Saunders M

更新日期：2009-10-01 00:00:00

abstract：PURPOSE:Efforts are underway in improving the informed consent process. The success of these efforts to improve quality of informed consent forms (ICFs) for phase I oncology trials has not been previously measured. METHODS:We reviewed and compared ICFs of all phase I trials for metastatic cancer conducted between 1986...

journal_title：Cancer chemotherapy and pharmacology

authors： Malik L,Cooper J

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:High cut-off dialysis, increasingly used in multiple myeloma patients, is susceptible to influence anticancer drug elimination. We report about lenalidomide disposition in a patient on high cut-off dialysis for renal failure secondary to myeloma cast nephropathy. METHODS:The patient received a higher dosa...

journal_title：Cancer chemotherapy and pharmacology

authors： Dao K,Lu Y,Peer CJ,Figg WD,Stadelmann R,Burnier M,Buclin T,Kissling S

更新日期：2017-01-01 00:00:00

abstract：:Plasma and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-OL) were measured fluorometrically after high-pressure liquid chromatography at 1, 3, and 24 h following one, nine, and 24 doses of 1.0 mg DXR/kg or one and eight doses of 4.0 mg DXR/kg, IP, to rats. Comparison of plasma levels of DXR found following...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters JH,Gordon GR,Kashiwase D,Acton EM

更新日期：1981-01-01 00:00:00

abstract：PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue ag...

journal_title：Cancer chemotherapy and pharmacology

authors： Schroeder PE,Jensen PB,Sehested M,Hofland KF,Langer SW,Hasinoff BB

更新日期：2003-08-01 00:00:00

abstract：PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang G,Zhan Y,Wang H,Li W

更新日期：2012-03-01 00:00:00

abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...

journal_title：Cancer chemotherapy and pharmacology

authors： Junor E,Davies J,Habeshaw T,Kaye S,Paul J,Rankin E,Reed N,Symonds RP

更新日期：1991-01-01 00:00:00

abstract：:cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients. Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2. Following this, doses were given every 4 weeks and escalated from 300...

journal_title：Cancer chemotherapy and pharmacology

authors： Calvert AH,Harland SJ,Newell DR,Siddik ZH,Jones AC,McElwain TJ,Raju S,Wiltshaw E,Smith IE,Baker JM,Peckham MJ,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：:The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was no...

journal_title：Cancer chemotherapy and pharmacology

authors： Di Fronzo G,Bertuzzi A,Ronchi E,Villani FP,Ronchetti L

更新日期：1979-01-01 00:00:00

abstract：OBJECTIVE:Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pothuri B,Brodsky AL,Sparano JA,Blank SV,Kim M,Hershman DL,Tiersten A,Kiesel BF,Beumer JH,Liebes L,Muggia F

更新日期：2020-04-01 00:00:00

abstract：:The cellular metabolism of 3'-amino-2',3'-dideoxycytidine (3'-NH2-dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside (ara-C) in cells that displayed dCydD activity (HeLa) and in cells that did not (L1210). Growth i...

journal_title：Cancer chemotherapy and pharmacology

authors： Mancini WR

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. The objective of this study was to evaluate whether body sur...

journal_title：Cancer chemotherapy and pharmacology

authors： Imai H,Kuwako T,Kaira K,Masuda T,Miura Y,Seki K,Sakurai R,Utsugi M,Shimizu K,Sunaga N,Tomizawa Y,Ishihara S,Ishizuka T,Mogi A,Hisada T,Minato K,Takise A,Saito R,Yamada M

更新日期：2017-03-01 00:00:00

abstract：:Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastr...

journal_title：Cancer chemotherapy and pharmacology

authors： Joel SP,Clark PI,Slevin ML

更新日期：1995-01-01 00:00:00

abstract：:CI-958, a new DNA-intercalating drug derived from a series of substituted 2H-[1] benzothiopyrano[4,3,2-cd]indazoles, is being tested in clinical trails because of its curative properties against murine solid tumor models and because it has demonstrated activity in a pilot phase II study of patients with hormone-refrac...

journal_title：Cancer chemotherapy and pharmacology

authors： Lun L,Sun PM,Trubey CM,Bachur NR

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:To compare the in vitro cytotoxicity of nedaplatin, an investigational platinum analog, with that of the standard platinum agents, cisplatin and carboplatin, against fresh human, epithelial ovarian cancers. METHODS:The Hamburger-Salmon human tumor colony-forming assay (HTCA) was used to measure the chemosensit...

journal_title：Cancer chemotherapy and pharmacology

authors： Alberts DS,Fanta PT,Running KL,Adair LP Jr,Garcia DJ,Liu-Stevens R,Salmon SE

更新日期：1997-01-01 00:00:00

abstract：OBJECTIVES:We evaluated whether DNA repair gene polymorphisms had an effect on clinical outcomes in metastatic/recurrent nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based chemotherapy. MATERIALS AND METHODS:Clinical data of 101 patients with metastatic/recurrent NPC between 2004 and 2011 were review...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen C,Wang F,Wang Z,Li C,Luo H,Liang Y,An X,Shao J,Li Y

更新日期：2013-08-01 00:00:00

abstract：:Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu K,Loo TL

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

更新日期：2005-09-01 00:00:00

abstract：:Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

journal_title：Cancer chemotherapy and pharmacology

authors： Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Paclitaxel and docetaxel are two taxanes approved for the treatment of non-small-cell lung cancer (NSCLC). However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). The aim of our study was to evaluate the response to docetaxel in...

journal_title：Cancer chemotherapy and pharmacology

authors： Macedo-Pérez EO,Morales-Oyarvide V,Mendoza-García VO,Dorantes-Gallareta Y,Flores-Estrada D,Arrieta O

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

更新日期：2004-08-01 00:00:00

abstract：PURPOSE:The ErbB family members are protein tyrosine kinases, which play a crucial role in the signal transduction pathways that regulate key cellular functions. Overexpression of the ErbB family members is associated with oncogenicity, metastatic potential, cell proliferation, apoptosis, angiogenesis, and prognosis in...

journal_title：Cancer chemotherapy and pharmacology

authors： Fu XH,Li J,Huang JJ,Zheng S,Zhang SZ

更新日期：2011-12-01 00:00:00

abstract：:A sensitive solid-phase-extraction and high-performance liquid chromatography (HPLC) method has been developed to investigate the pharmacokinetics and metabolism of the hypoxic-cell cytotoxic agent tirapazamine (1,2,4-benzotriazine-3-amine 1,4-di-N-oxide; WIN 59075, SR 4233), currently in phase I/II studies in the Uni...

journal_title：Cancer chemotherapy and pharmacology

authors： Robin H Jr,Senan S,Workman P,Graham MA

更新日期：1995-01-01 00:00:00

abstract：:Chemobrain refers to a common sequela experienced by a substantial subset of cancer patients exposed to chemotherapeutic treatment, a phenomenon that dramatically deteriorates the survivors' quality of life and prevents them from restoring their pre-cancer life. This review is intended to address the current knowledge...

journal_title：Cancer chemotherapy and pharmacology

authors： El-Agamy SE,Abdel-Aziz AK,Esmat A,Azab SS

更新日期：2019-07-01 00:00:00

abstract：PURPOSE:The aim was to investigate in patients receiving doxorubicin whether any alteration in myocardial oxidative metabolism or blood flow as assessed by positron emission tomography (PET) could be observed either after the first dose of the drug, or during its chronic administration. METHODS:Six female non-heart-fa...

journal_title：Cancer chemotherapy and pharmacology

authors： Nony P,Guastalla JP,Rebattu P,Landais P,Lievre M,Bontemps L,Itti R,Beaune J,Andre-Fouet X,Janier M

更新日期：2000-01-01 00:00:00